Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will participate in a fireside chat at the Bank of America Securities 2023 Health Care Conference on May 11, 2023, at 11:40 AM PDT. Interested parties can register for the live webcast through a provided link.
A live audio broadcast will be available on the investor section of Esperion's website, with a replay set to be accessible about two hours post-event and archived for roughly 90 days.
Esperion is focused on developing medicines for patients with cardiovascular diseases, addressing the urgent need for effective treatments to lower LDL-cholesterol levels.
Esperion (NASDAQ: ESPR) announced it will report its first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. Following this, management will host a webcast at 8:00 a.m. ET to discuss the financial results and business progress. The event will be accessible through the investor section of the Esperion website, with a replay available approximately two hours later. Esperion is focused on developing innovative medicines for patients with cardiovascular and cardiometabolic diseases, particularly aiming to manage high cholesterol levels effectively.
Esperion (NASDAQ: ESPR) has announced a performance-based agreement with Currax Pharmaceuticals, allowing Currax’s 72 sales representatives to co-promote its cholesterol-lowering products, NEXLETOL® and NEXLIZET®. This partnership significantly increases the sales force for these products, reflecting Esperion’s commitment to sustained growth. The agreement aims to leverage the positive momentum from the CLEAR Outcomes trial, involving nearly 14,000 patients, which evaluated the cardiovascular benefits of NEXLETOL. Both medications are indicated for patients requiring additional LDL-C reduction. Important safety information includes warnings about hyperuricemia and tendon rupture. The collaboration lasts through the end of 2023, focusing on elevating awareness and utilization of these treatments.
Esperion (NASDAQ: ESPR) has announced that Sheldon Koenig, the company's president and CEO, will participate in a fireside chat at Needham's 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:45 AM ET. This event will provide insights into the company's innovative approaches in treating cardiovascular and cardiometabolic diseases. Interested parties can register for the live webcast through the provided link. A recorded version will be available for 90 days post-event.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
